Comparative Pharmacology
Head-to-head clinical analysis: TESTRED versus TREST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TESTRED versus TREST.
TESTRED vs TREST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone is an androgen receptor agonist, promoting development of male secondary sexual characteristics and anabolic effects.
Mirtazapine is a tetracyclic antidepressant that acts as a potent antagonist of central α2-adrenergic autoreceptors and heteroreceptors, leading to increased norepinephrine and serotonin neurotransmission. It also antagonizes 5-HT2 and 5-HT3 receptors, with no significant effect on serotonin reuptake.
Testosterone enanthate 200 mg intramuscularly every 2 weeks.
10-15 mg orally every 6 hours as needed for agitation in dementia; maximum 60 mg/day.
None Documented
None Documented
Terminal elimination half-life for testosterone is 2-4 hours; testosterone enanthate has a half-life of 4-5 days due to slow release from the oily depot. Clinical context: shorter half-life requires more frequent dosing for stable serum levels.
Terminal elimination half-life: 4–6 hours (clinically, dosing every 6–8 hours maintains therapeutic levels).
Approximately 90% of administered testosterone is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites (androsterone, etiocholanolone). About 6% is excreted in feces via bile. Unchanged testosterone excretion is negligible (<1%).
Renal: 80% unchanged; biliary/fecal: 10% as metabolites; 10% other.
Category C
Category C
Androgen
Androgen